Form 483

SCA Pharmaceuticals, Inc. Form 483, 2014-04-02

FDA issued a Form 483 to SCA Pharmaceuticals, Inc. on 2014-04-02 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

SCA Pharmaceuticals, Inc. · Little Rock, United States · Issued April 2, 2014

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

2 Apr 2014
21 CFR 211.28(a)

Clothing appropriate for duties performed

Cited by Linda F Murphy, Zachery L Miller

2 Apr 2014
21 CFR 211.42(c)(10)(v)

Cleaning System

Cited by Linda F Murphy, Zachery L Miller

2 Apr 2014
21 CFR 211.42(c)(10)(vi)

Equipment to control conditions

Cited by Linda F Murphy, Zachery L Miller

2 Apr 2014
21 CFR 211.56(a)

Sanitation--buildings not clean, free of infestation

Cited by Linda F Murphy, Zachery L Miller

2 Apr 2014
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Linda F Murphy, Zachery L Miller

Inspected site

SPSCA Pharmaceuticals, Inc.Little Rock, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.28(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(vi)Cited across public-safe Form 483 observations1x
21 CFR 211.56(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 7 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere